Home / 2021 / April / 29

Daily Archives: April 29, 2021

Aviation Week Network’s MRO Americas wrapped up in Orlando today with a sold-out conference and 8,500 registered attendees

NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) — The aviation MRO community gathered in Orlando this week, in-person for the first time in over a year at Aviation Week Network’s 26th Annual MRO Americas (#MROAM). The event was held at the Orange County Convention Center with a sold-out conference and more than 8,500 registered attendees, with more than 75% opting for the in-person experience. The aviation community generated nearly $20 million into Orlando’s economy. The event was co-located with the Military Aviation Logistics & Maintenance Symposium (#MALMS), which was also sold out.

Anyone who was unable to travel to Orlando will be able to participate virtually by registering here. Conference sessions will be available on demand, and networking will be accommodated May 4-5.

“We were so thrilled with the incredible turn out and the response received from attendees, who were busy networking, signing contracts and receiving premium content from top industry speakers,” said Lydia Janow, Managing Director, Events, for Aviation Week Network. “We are inspired by how the industry has pulled together to support each other, and we’ve gotten high demand for our upcoming events, including next year’s MRO Americas, which will be held in Dallas, April 26-28.”

The conference addressed how the industry is moving forward after a year of incredible challenges and change with speakers from American Airlines, Boeing, Airbus, Ameriflight, and more. Speakers included:

  • David Seymour, COO, American Airlines
  • Bobbi Wells, Vice President, Safety & Airworthiness, Air Operations, FedEx Express
  • Paul Kinstedt, SVP & COO, Republic Airways
  • Paul Chase, CEO, Ameriflight
  • Danielle Vardaro, Head of Worldwide Customer Support & Aftermarket Sales Embraer
  • John Brooks, Manager, Commercial Airframe Parts, Boeing Global Services
  • Giovanni Spitale, VP of Commercial Parts, Boeing Global Services
  • Daniel WennigerVP, Upgrade Services, Airbus
  • Dana Donati, GM & Director of Academic Programs, LIFT Academy, A Republic Airways Company
  • Pat Foley, CEO, Lufthansa Technik Puerto Rico
  • Nicole Huque, Managing Director, Global Aviation, Aerospace & Defense, Krauthamer & Associates (K&A)
  • Parimal (PK) Kopardekar PhD, Director, NASA Aeronautics Research Institute (NARI), NASA Ames Research Center
  • Karine Lavoie-Tremblay, Director, Business Relationship, Digital Technologies
  • Pratt & Whitney
  • Naveen Poonian, CEO, iBASE
  • Keren Rambow, Marketing Services Executive, GE Aviation
  • Fred Sontag, VP of Sales, Americas & VP Distribution Solutions Group, GA Telesis
  • Caroline Vandedrinck, SVP Business Development, SR Technics

“The Orange County Convention Center (OCCC) was thrilled to welcome back Aviation Week Network’s MRO Americas and its members to Orlando,” said OCCC Executive Director Mark Tester. “This week, MRO Americas hosted thousands of attendees in our North-South Building. I saw firsthand how staggered attendance, proper social distancing through signage, floor stickers and safety protocols were implemented to create a safe and controlled gathering. We have a stellar reputation for customer service, flexibility, and doing the right thing. We also have great relationships with our clients and a supportive community that is focused on the health and safety of our guests.”

The Military Aviation Logistics & Maintenance Symposium was supported by Elbit Systems of AmericaFTIL3 HarrisLogistics Officers Association (LOA), Robbins Gioia and Teledyne Controls.

MRO Americas was supported by our sponsors.   Platinum Sponsors are AirbusChromalloyGE AviationHoneywellLufthansa Technik, and ST Engineering. Gold Sponsors are ATSAvparts InternationalBPAero, CTS EnginesEmbraerGlobalParts AeroIFSLCIMB AerospaceNordamSpirit AerosystemsVertical Aerospace, and VSE Aviation.

ABOUT AVIATION WEEK NETWORK 
Aviation Week Network is the largest multimedia information and services provider for the global aviation, aerospace, and defense industries, serving 1.7 million professionals around the world. Industry professionals rely on Aviation Week Network to help them understand the market, make decisions, predict trends, and connect with people and business opportunities. Customers include the world’s leading aerospace manufacturers and suppliers, airlines, airports, business aviation operators, militaries, governments and other organizations that serve this worldwide marketplace. Aviation Week Network’s portfolio delivers award-winning journalism, data, intelligence and analytical resources, world-class tradeshows and conferences, and results-driven marketing services and advertising is helping our customers succeed.   Aviation Week Network is part of Informa Markets, a division of Informa PLC.

ABOUT INFORMA MARKETS
Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com.

CONTACT: Elizabeth Kelley Grace
561.702.7471
Elizabeth@thebuzzagency.net

A new collaboration between SNOMED International and ICH promotes seamless data exchange in support of public health

London, United Kingdom & Geneva, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) — SNOMED International and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) are announcing the release of important new maps between global medical terminologies SNOMED CT and MedDRA. This collaborative effort is the first deliverable of a new agreement entered into between SNOMED International and ICH.

ICH is an international non-profit organisation which brings together regulatory authorities and pharmaceutical industry from across the globe to discuss scientific and technical aspects of pharmaceuticals and to develop ICH guidelines. Owned by ICH, MedDRA, the Medical Dictionary for Regulatory Activities, is a rich and highly specific standardised medical terminology developed by ICH to facilitate sharing of regulatory information internationally for medical products used by humans and is used for registration, documentation and safety monitoring of medical products both before and after a product has been authorised for use.  SNOMED International is the not-for-profit organization that owns and maintains SNOMED CT, the world’s most comprehensive clinical terminology with over 350,000 concepts ranging across diagnosis, signs and symptoms and tens of thousands of surgical, therapeutic and diagnostic procedures.

This joint effort has produced two independent maps (MedDRA to SNOMED CT and SNOMED CT to MedDRA) which have been derived from frequently used and key pharmacovigilance MedDRA terms identified from the European Medicines Agency and the UK’s Medicines & Healthcare products Regulatory Agency.  In addition, a set of COVID-19 related terms are also included in the first production release of the maps to capture important aspects of the pandemic.

The maps are intended to facilitate the exchange of data between regulatory databases (which use MedDRA) and healthcare databases/electronic health records (which use SNOMED CT). In one use case, key pharmacovigilance concepts coded in SNOMED CT in an electronic health record (EHR) could be converted to MedDRA for the purpose of adverse event reporting to regulatory authorities or for the purposes of epidemiological research. In the opposite direction, these same key terms coded in MedDRA representing adverse events, warnings, and other regulatory information could be converted into SNOMED CT so that the information is available in the patient’s record to aid in clinical decision-making.

The two maps were created as part of a project involving SNOMED International and ICH entitled WEB-RADR 2.  Funded by the Innovative Medicines Initiative (IMI), a large-scale public-private partnership between the EU and the pharmaceutical industry association, EFPIA, IMI aims to boost biopharmaceutical innovation in Europe and to speed up the development of better and safer medicines for patients. With the creation of the maps from the WEB-RADR 2 project, both SNOMED International and ICH have committed to their ongoing use and maintenance extending past the conclusion of the project.

Mick Foy, Medicines and Healthcare products Regulatory Agency UK and Chair of the ICH MedDRA Management Committee said “This is an exciting development and an important milestone. Developing interoperability between SNOMED CT and MedDRA has been a long-standing ambition and will greatly enhance data collection for regulatory purposes and for drug safety research”.

SNOMED International CEO, Don Sweete, welcomes the evolution of the organization’s relationship with ICH. “It is exciting to see a long-term alliance borne from a collaborative project created to improve drug safety for patients and citizens. This agreement serves a joint commitment by two organizations dedicated to enabling health systems interoperability across regulatory and clinical continuums.”

The Production version of the two maps is being made available to licensed SNOMED CT and MedDRA users on April 30, 2021 and will be based on the January 2021 version of SNOMED CT and the September 2020 version of MedDRA. It is planned that the maps will be released annually in April.

To access the maps:

Visit SNOMED International or MedDRA’s Maintenance and Support Services Organization (MSSO) for map release documents, including:

  • MedDRA-SNOMED CT Mapping Conventions are available here for SNOMED CT users and here for MedDRA users.
  • Criteria for accepting requests for additions or changes to SNOMED CT to MedDRA map and MedDRA to SNOMED CT map is available here for SNOMED CT users and here for MedDRA users.
  • Map Change Request Tool (Map CR) and Map CR User Guide

For more information on these maps and resources, please contact MedDRA MSSO (mssohelp@meddra.org) or SNOMED International (info@snomed.org).

About SNOMED International:

SNOMED International is a not-for-profit organization that owns and develops SNOMED CT, the world’s most comprehensive healthcare terminology product. We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms. This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community. SNOMED International is the trading name of the International Health Terminology Standards Development Organisation.

To learn more about SNOMED International and SNOMED CT, visit www.snomed.org.

About the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is an international non-profit organisation unique in bringing together the regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of pharmaceuticals and develop ICH guidelines. ICH’s mission is to achieve greater harmonisation worldwide to ensure that safe, effective and high quality medicines are developed, and registered and maintained in the most resource efficient manner whilst meeting high standards. MedDRA has been developed by ICH and is continuously enhanced to meet the evolving needs of regulators and industry around the world.

To learn more about the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and MedDRA, visit www.ich.org and www.meddra.org.

Attachment

Kelly Kuru
SNOMED International
comms@snomed.org

ICH Secretariat
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
pressrelease@ich.org

Modelo is Giving Away $250,000 Worth of Beer so Fans Can #SaludToCinco on Cinco de Mayo

Modelo is awarding prizes so people 21+ can celebrate, connect on social and raise a glass to the heroes who got us here

CHICAGO, April 29, 2021 (GLOBE NEWSWIRE) — This Cinco de Mayo, Modelo is giving away $250,000 worth of beer, in the form of $10 gift cards, so fans can join in on a celebratory #SaludToCinco social toast on Wednesday, May 5 – a virtual “salud” to connect. Additionally, Modelo, the beer brewed with The Fighting Spirit™, is again supporting #FirstRespondersFirst with a donation to salute the ongoing tireless efforts of first responders.

“At Modelo, we believe the best celebrations happen when we’re able to reconnect with friends and family,” said Greg Gallagher, Vice President, Modelo Brand Marketing. “That’s why we’re picking up the tab this Cinco de Mayo so fans can raise a glass to the heroes who’ve had our backs this past year.”

Now through noon on May 4, those 21+ can visit ModeloCincodeMayo.dja.com or follow @ModeloUSA on social to learn how to enter for a chance to win a $10 e-gift card that can be used to purchase a 6-pack of Modelo.* Modelo will then encourage fans of legal drinking age to join the social toast on Cinco de Mayo, honoring first responders and tagging the heroes in their lives with the hashtag #SaludToCinco.

Modelo will continue its support of first responders with a $250,000 donation to #FirstRespondersFirst, an organization dedicated to the wellbeing of healthcare workers. Modelo has always been committed to honoring those with The Fighting Spirit, a core part of the brand’s DNA. Last year Modelo donated $750,000 to #FirstRespondersFirst to provide essential supplies, equipment, and resources to protect healthcare workers on the frontline.

To bring to life the essence of #SaludToCinco, Modelo recently teamed up with Mario Lopez – actor, media personality, and brand fan – to surprise a group of healthcare workers in his hometown of Burbank, Calif. While at the hospital, they expressed appreciation of the staff’s hard work and sacrifices while treating them to local Mexican food.

*About the Sweepstakes: NO PURCHASE NECESSARY. Open to 50 US/DC, 21+. Ends 5/4/21 at 11:59 AM ET. Void where prohibited. Rules: modelocincodemayo.dja.com

About Modelo®

Born in 1925 in the small town of Tacuba, Mexico, Modelo has been bringing distinctive high-quality beer to people ever since, including Modelo Especial®, Modelo Negra®, Modelo Chelada Especial™, Modelo Chelada Tamarindo Picante™, Modelo Chelada Limón y Sal™ and Modelo Chelada Mango y Chile™. Modelo Especial is a golden, full-flavored Pilsner-style Lager with a clean, crisp finish whose original recipe was first brewed under the vision to create a ‘model’ beer. As the #1 imported beer in the U.S., Modelo Especial surpassed 100MM cases sold in 2018. The Modelo family of beers are exclusively brewed, imported and marketed for the U.S. by Constellations Brands.

MEDIA CONTACT:
Angie Taylor
angie.taylor@zenogroup.com

Taconic Biosciences Launches New COVID-19 Mouse Model

Expands COVID-19 Research Toolkit with novel hACE2 AC22 Mouse

RENSSELAER, N.Y., April 29, 2021 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of a new COVID-19 mouse model. This human ACE2 (hACE2) transgenic mouse expands Taconic’s COVID-19 research toolkit.

In October 2020, Taconic launched its first hACE2 model. The AC70 mouse experiences a lethal response to infection by SARS-CoV-2, the virus that causes COVID-19. Conversely, the new AC22 mouse is lethality-resistant, enabling therapeutic, vaccine, and post-infection symptom research.

Although various hACE2 mouse models of lethal SARS-CoV-2 infection exist, the hACE2 AC22 lethality-resistant model is important because it permits study of sublethal infection. Most humans infected with SARS-CoV-2 survive, and an animal model which replicates sublethal disease and recovery is needed. The hACE2 AC22 mouse provides a longer study window to assess drug efficacy compared to lethal infection models.

“While vaccines bring hope of an end to the pandemic, research on COVID-19 is still needed,” shared Dr. Michael Seiler, vice president of commercial models at Taconic. “There is a huge population of people who have now had the disease. We need models that also survive this disease long enough to aid in replicating that human condition. It cannot be overstated just how important this new AC22 model is in enabling that research.”

Study ready cohorts of animals are available for immediate ordering.

To learn more about hACE2 mice or Taconic’s Coronavirus Toolkit, please contact Taconic at 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.

About Taconic Biosciences, Inc.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia, and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact: Kelly Owen Grover
Director of Marketing Communications
(518) 697-3824
kelly.grover@taconic.com

Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting

– Toripalimab data will also be featured in ASCO’s official press program –

SHANGHAI, China, and REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that a late-breaking abstract detailing clinical data of anti-PD-1 antibody, toripalimab, in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma will be featured at ASCO 2021 in the plenary session on Sunday, June 6, 2021. The abstract has also been selected for ASCO’s official press program.

Details regarding the plenary session and abstract publication are as follows:

Title: JUPITER-02: Randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC)
Abstract #: LBA2
Presentation: Plenary session, June 6, 2021, 1:00 p.m. – 4:00 p.m. Eastern Daylight Time
Publication: June 3, 2021, 5:00 p.m. Eastern Daylight Time

“We are excited that results of JUPITER-02, a Phase 3 clinical trial evaluating toripalimab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma, have been selected for presentation during ASCO’s plenary session, which traditionally features high-impact studies,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. “Treatment of nasopharyngeal carcinoma, a specific type of head-and-neck cancer, is challenging, as the diagnosis usually occurs when the cancer is in an advanced stage and treatment options are limited.”

In addition to the JUPITER-02 late-breaking abstract, ASCO accepted for publication or presentation more than two dozen additional abstracts, primarily investigator-sponsored studies, that evaluate the utility of toripalimab in a variety of cancer types including lung cancer, melanoma, urothelial carcinoma, gastroesophageal cancer and hepatobiliary malignancies.

About Toripalimab

More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally, including in China and the United States. Pivotal clinical trials are ongoing or completed evaluating the safety and efficacy of toripalimab for a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

In China, Toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®). On December 17, 2018, Toripalimab was granted a conditional approval from the National Medical Products Administration (NMPA) for the second-line treatment of unresectable or metastatic melanoma. In December 2020, Toripalimab was successfully included in the updated National Reimbursement Drug List. In February 2021, the supplemental NDA for Toripalimab in combination with chemotherapy for the first-line treatment of patients with advanced, recurrent or metastatic nasopharyngeal carcinoma was accepted by the NMPA. In the same month, the NMPA granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after failure of at least two lines of prior systemic therapy. In April 2021, NMPA granted a conditional approval to toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

In the United States, a rolling submission of the first toripalimab Biologics License Application (BLA) is underway for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). The U.S. Food and Drug Administration (FDA) has granted toripalimab Breakthrough Therapy Designation for this indication. There are currently no PD-1 blocking antibodies indicated for use in NPC in the United States. Additionally, FDA has granted Fast Track status for the development of toripalimab for the treatment of mucosal melanoma as well as orphan drug designation for NPC, mucosal melanoma and soft tissue sarcoma. Earlier in 2021 Coherus in-licensed rights to develop and commercialize toripalimab in the United States and Canada. Coherus and Junshi Biosciences plan to file additional toripalimab BLAs with the FDA over the next three years for multiple rare cancers and highly prevalent cancers.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 28 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology Chinese Academy of Science and Eli Lilly to co-develop JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has received Emergency Use Authorization (EUA) by US FDA in Feb 2021 for the treatment of recently diagnosed, mild to moderate COVID-19 in patients who are at high risk of progressing to severe COVID-19 and/or hospitalization. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

About Coherus BioSciences
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system.

In February 2021, Coherus and Junshi Biosciences announced a collaboration in which Coherus would in-license toripalimab, an anti-PD-1 antibody, in the United States and Canada. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business. Coherus markets UDENYCA® (pegfilgrastim-cbqv) in the United States and through 2023 expects to launch biosimilars of Humira®, Avastin® and Lucentis®, if approved.

For additional information, please visit www.coherus.com.

UDENYCA® is a trademark of Coherus BioSciences, Inc.
Avastin® and Lucentis® are registered trademarks of Genentech, Inc.
Humira® is a registered trademark of AbbVie Inc.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Coherus’ ability to generate cash flow from its UDENYCA® business; Coherus’ and Junshi Biosciences’ ability to co-develop toripalimab, and Coherus’ ability to commercialize toripalimab, or any other drug candidates developed as part of its collaboration with Junshi Biosciences in the licensed territory; Coherus’ ability to expand a late-stage pipeline into the rapidly growing checkpoint inhibitor market; any market size expectation for checkpoint inhibitor therapeutic agents in the United States; the potential for toripalimab to gain approval in the United States for nasopharyngeal carcinoma or any indication; toripalimab’s possibility to be the first marketed Chinese anti-PD-1 antibody in the overseas market; Coherus’ and Junshi Biosciences’ plans to file additional toripalimab BLAs with the FDA over the next three years for any clinical indication; Coherus’ plans to invest the cash generated by its biosimilar commercial business to build a focused immuno-oncology franchise; Coherus’ ability to prepare for projected launches through 2023 of biosimilars of Humira®, Avastin® and Lucentis®, if approved.

Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risk that the parties are unable to obtain clearance under the Hart-Scott Rodino Antitrust Improvements Act, from the Committee on Foreign Investment in the United States, or any other statute or regulatory agency having jurisdiction with respect to the proposed transactions, the risks and uncertainties inherent in the clinical drug development process; the risks and uncertainties of the regulatory approval process, including the timing of Coherus’ regulatory filings; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus’ drug candidates; and the risks and uncertainties of possible patent litigation. All forward-looking statements contained in this press release speak only as of the date on which they were made. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on February 25, 2021, and its future periodic reports to be filed with the Securities and Exchange Commission. Our results for the year ended December 31, 2020 are not necessarily indicative of our operating results for any future periods.

Junshi Biosciences Contact Information

IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-2250 0300

Solebury Trout
Bob Ai
bai@soleburytrout.com
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

Coherus BioSciences Contact Information:

IR Contact
McDavid Stilwell
Coherus BioSciences, Inc.
mstilwell@coherus.com

Media Contact
Denise Powell
denise@redhousecomms.com

 

Wasabi Secures $112M Series C Financing, Sets Sights on Global Expansion and Company Growth

Wasabi triples valuation as it continues to establish first hyperscale cloud storage architecture

Boston, MA, April 29, 2021 (GLOBE NEWSWIRE) —  Wasabi, the hot cloud storage company, today announced $112M in Series C funding led by Fidelity Management & Research Company with participation from existing investors. The round follows Wasabi’s $27.5M in debt financing announced in January. The C round brings Wasabi’s total equity financing to $219 million.

The valuation of the C round was roughly triple the valuation of the company’s most recent equity round, which closed almost exactly one year ago. Wasabi’s revenue and storage under management has also tripled in the last year with deployed storage recently passing one exabyte. The company has 22,000 customers worldwide, and Wasabi’s channel network more than doubled to over 5,000 partners worldwide. The company has data centers in the US, Europe and Japan.

Proceeds from this funding will be used to expand the company’s network of resellers, technology alliance partners, and distributors, open data centers in many new international markets, and to significantly grow its internal team across all fronts including development, sales, support, marketing, administration and operations. The company will also use the proceeds to make further investments in building its brand internationally and providing additional marketing support for its channel partners.

“This new funding is a watershed event for Wasabi,” said Wasabi CEO & Co-Founder David Friend. “With revenues tripling for each of the last 3 years and over $100M of new investment led by one of the world’s largest and most prestigious financial institutions, our customers will know that their data is in the hands of a reliable, fast-growing company with the substantial resources to meet their growing needs. Storing the world’s data in the cloud is one of the biggest opportunities in the IT industry, and we are now well-positioned to secure a leadership role in the evolution of the cloud. We will continue to invest in our proprietary software, grow our channel, enhance our brand and expand storage capacity around the world.”

Wasabi is redefining the way businesses think about cloud storage by offering a solution that is 1/5th the cost of Amazon S3, has zero fees for egress or API requests and requires no vendor lock-in. With cloud data storage growing 60% year over year, low-cost, highly reliable and infinitely scalable cloud storage is in demand by a wide range of organizations. It’s an ideal product for the channel because every organization needs to store data, it’s simple to learn to sell, and channel partners enjoy healthy margins. Wasabi’s rapidly expanding customer base stores every imaginable type of data ranging from backups, DR and archiving to surveillance, medical imaging, big science, education, genomics, AI/ML data lakes, television, movies and government data.

“The cloud IaaS market has experienced tremendous growth over the last year, primarily fueled by businesses’ needs to support new ways of working, while also delivering more digital goods and services to customers.” said Andrew Smith, Research Manager, Cloud Infrastructure Services at IDC. “As cloud data migrations and hybrid cloud adoption continues to accelerate, Wasabi is well-positioned to deliver IaaS storage solutions that meet buyer needs for consistent, transparent pricing, as well as integration across multiple cloud and on-premises storage environments.”

J.P. Morgan Securities LLC served as lead placement agent and Lincoln International served as a co-placement agent to Wasabi in connection with this funding. Foley & Lardner served as counsel to the company.

For more information on Wasabi’s hot cloud storage, please visit Wasabi.com.

About Wasabi

Wasabi provides simple, predictable and affordable hot cloud storage for businesses all over the world. It enables organizations to store and instantly access an infinite amount of data at 1/5th the price of the competition with no complex tiers or unpredictable egress fees. Trusted by tens of thousands of customers worldwide, Wasabi has been recognized as one of technology’s fastest-growing and most visionary companies. Created by Carbonite co-founders and cloud storage pioneers David Friend and Jeff Flowers, Wasabi has secured nearly $250 million in funding to date and is a privately held company based in Boston.

Follow and connect with Wasabi on Twitter, Facebook, Instagram and our blog.

Nick Brown
InkHouse for Wasabi
wasabi@inkhouse.com

Nevilles Extends TrueCommerce’s Digital Solutions to Accelerate Digital Transformation with the Adoption of PIM

Leading supplier of tableware and light catering equipment chooses TrueCommerce Product Manager to optimise the management and distribution of product data

COVENTRY and MANCHESTER, United Kingdom, April 29, 2021 (GLOBE NEWSWIRE) — TrueCommerce, a global provider of trading partner connectivity, integration and digital commerce solutions, announced today that Neville UK PLC has adopted TrueCommerce Product Manager, its Product Information Management (PIM) system. Nevilles, an industry leading supplier of tableware and light catering equipment to the UK and Irish food service industry, will leverage the system alongside its existing TrueCommerce EDI and B2B eCommerce solutions to further accelerate its digital transformation.

“We previously relied on our ERP system for storing our product data, however it wasn’t designed to be used in this way and was therefore clunky and not particularly user friendly. It also involved the use of multiple spreadsheets which meant that launching new products was convoluted and unstructured.” said Ian Witsey, Product Manager at Nevilles. “When the COVID-19 pandemic hit and more of our customers pivoted their operations into the B2C market, we saw a considerable increase in the number of customer queries regarding the product data they needed for their new online channels. Quite simply our existing processes could not support our customers in the way we wanted to, and as a company that places great value on strong customer relationships, we quickly made the decision to look for a PIM system.”

The TrueCommerce Product Manager solution will provide Nevilles with a centralised master repository for storing, managing, optimising and publishing product data, with much less effort and fewer resources required. The system will assist the company with its new product development programme, which launches over 400 new products a year, ensuring that its customers have access to all the new product data quickly and easily, thereby reducing time-to-market. The solution will also enable Nevilles to provide its customers with data tailored to the specific requirements of their sales channels, for example descriptions optimised for Sales Partners and marketplaces.

“We evaluated a number of PIM systems, however as an existing TrueCommerce customer, having already implemented the TrueCommerce EDI and B2B eCommerce solutions, we were confident that TrueCommerce was the best option. The solution had all the functionality we required and the company understood our business and requirements.” said Ian Witsey.

“We are delighted that Nevilles have expanded its use of the TrueCommerce suite of digital commerce solutions with the adoption of our PIM system,” said David Grosvenor, Managing Director at TrueCommerce Europe. “We look forward to continuing to support Nevilles on the company’s digital transformation journey.”

TrueCommerce’s Product Manager is part of a broader set of digital commerce services and applications that drive sales and create a seamless omni-channel experience by reducing complexity and increasing scalability. The platform manages all business critical flows with a single connection to your ERP and a single repository for all product and inventory data, which can then be consistently published across hundreds of sales channels.

For more information, visit, https://www.truecommerce.com/uk-en/solutions/pim-product-information-management.

About Nevilles

Since 1965, Nevilles have provided tableware and light catering equipment to the hospitality industry. As a family owned and managed business, Nevilles places great value upon developing strong working relationships with our customers.

More information on Nevilles can be found at https://www.nevilleuk.com/

About TrueCommerce

TrueCommerce is the most complete way to connect your business across the supply chain, integrating everything from EDI, to inventory management, to fulfillment, to digital storefronts and marketplaces, to your business system, and to whatever comes next. To stay ahead in today’s dynamic global market, companies need to be able to do business in a lot of different directions at once. But too often, doing so means too many solutions and too much assembly required. For decades TrueCommerce has helped businesses be more connected, more supported, and more prepared for what’s next. That’s why thousands of companies – ranging from startups to the FTSE 100, across various industries – rely on us.

TrueCommerce: Do business in every direction

For more information, visit https://www.truecommerce.com/uk-en.

Media Contact
Yegor Kuznetsov, TrueCommerce
703-209-0167
yegor.kuznetsov@truecommerce.com